Lab Dept: Chemistry

Test Name: BRIVARACETAM, PLASMA

General Information

Lab Order Codes:	BRIVA
Synonyms:	Briviact
CPT Codes:	80299- Quantitation of therapeutic drug, not elsewhere specified
Test Includes:	Brivaracetam concentration in plasma, reported in mcg/mL

Logistics

Test indications:	To determine brivaracetam concentration in plasma.
Lab Testing Sections:	Chemistry - Sendouts
Referred to:	Mayo Clinic Laboratories (MML Test: BRIVA)
Phone Numbers:	MIN Lab: 612-813-6280 STP Lab: 651-220-6550
Test Availability:	Daily, 24 hours. See Collection for suggested draw times.
Turnaround Time:	1-2 days
Special Instructions:	N/A

Specimen

Specimen Type:	Blood
Container:	Lavender top tube (EDTA) Alternative: Green top sodium or lithium heparin, light blue top sodium citrate.
Draw Volume:	3 mL (minimum: 1.5 mL) blood
Processed Volume:	1 mL (minimum: 0.5 mL) plasma

Collection:	Routine blood collection, drawn immediately before next scheduled dose. For sustained-release formulations only, draw blood a minimum of 12 hours after last dose.
Special Processing:	Lab Staff: Within 2 hours of collection, centrifuge specimen, aliquot plasma to plastic vial and refrigerate. Store and ship at refrigerated temperatures Specimen stable refrigerated (preferred), frozen or ambient for 28 days.
Patient Preparation:	N/A
Sample Rejection:	Specimens collected in unacceptable container; mislabeled or unlabeled specimens

Interpretive

Reference Range:	0.2-2.0 mcg/mL Interpretive information from reference lab: The report is intended for use by a physician to determine if the patient is receiving a dose sufficient to achieve a therapeutic effect or to assess whether the patient is compliant with prescribed dose. The reference range represents the concentrations observed to be associated with greatest drug efficacy without side effects or toxicity. Most individuals display optimal response to brivaracetam with plasma levels 0.2 to 2.0 mcg/mL. Some individuals may respond well outside of this range or may display toxicity within the therapeutic range; thus, interpretation should include clinical evaluation. Toxic levels have not been well established. Therapeutic ranges are based on specimens collected at trough (ie, immediately before the next dose).
Critical Values:	N/A
Limitations:	N/A
Methodology:	Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
References:	Mayo Clinic Labs (July 2024)
Updates:	7/31/2024: Initial entry. Replaces obsolete FBRIV.